PROVIDER POLICIES & PROCEDURES

Size: px
Start display at page:

Download "PROVIDER POLICIES & PROCEDURES"

Transcription

1 PROVIDER POLICIES & PROCEDURES BRCA GENETIC TESTING The purpose of this document is to assist providers enrolled in the Connecticut Medical Assistance Program (CMAP) with the information needed to support a medical necessity determination for BRCA Mutation Testing for breast and ovarian cancer susceptibility. By clarifying the information needed for prior authorization of services, HUSKY Health hopes to facilitate timely review of requests so that individuals obtain the medically necessary care they need as quickly as possible. Genetic testing provides information that can be used to diagnose genetic diseases and susceptibility to diseases or conditions that are inherited. Such testing includes studying chromosomes to the level of individual genes, biochemical testing for the possible presence of genetic diseases, and identifying mutant forms of genes associated with increased risk of developing genetic disorders. The results of a genetic test can be used to confirm or rule out a genetic condition or to help determine an individual s chance of developing a genetic condition or passing on a genetic disorder. Results are often used to influence choices about health care and management of an identified genetic disorder or susceptibility to one. Several hundred genetic tests are currently available. The use of genetic testing for point mutations in the BRCA1 and BRCA2 genes may influence individual management in a variety of ways. The results of BRCA Mutation Testing can provide individuals with the information necessary to make fully informed health-care decisions. Individuals with point gene mutation may consider increased surveillance for breast cancer, or consider a prophylactic mastectomy or oophorectomy. Family members of an individual with a known point mutation, who test negative for a mutation, can forego increased surveillance and/or consideration of prophylactic surgery. Genetic testing for point mutations BRCA1 and BRCA2 genes has emerged as a widely accepted test, when accompanied by genetic counseling. The BRACAnalysis Rearrangement Test (BART) is a refinement of the BRCA genetic tests and is purported to detect rare, large rearrangements of deoxyribonucleic acid (DNA) in the BRCA 1 and BRCA 2 genes which were previously undetected by standard genetic testing. The manufacturer (Myriad Genetic Laboratories) reports that BART testing will identify an additional approximate 3% of BRCA 1 and BRCA2 mutations in very high-risk families and is intended for use only in women at an exceptionally high risk for breast cancer who have previously tested negative for BRCA 1 and BRCA 2 sequence mutations. CLINICAL GUIDELINE Coverage guidelines for molecular testing for breast and/or ovarian cancer BRCA Mutation Testing are made in accordance with the DSS definition of Medical Necessity and in line with published recommendations and guidelines disseminated by organizations including the U.S. Preventive Services Task Force, the American College of Medical Genetics, and the National Comprehensive Cancer Network. The following criteria are guidelines only. Coverage determinations are based on an 1

2 assessment of the individual and his or her unique clinical needs. If the guidelines conflict with the definition of Medical Necessity, the definition of Medical Necessity shall prevail. The guidelines are as follows: Testing for the purpose of diagnosing a genetic disorder or identifying an individual who is at risk for a late onset or slowly evolving genetic disorder may be considered medically necessary when: 1. A specific mutation or set of mutations has been identified and broadly accepted by credible medical societies to be reliably associated with the condition; and 2. The genetic disorder cannot be identified through biological or other testing; and 3. The individual displays clinical features of or may be at increased risk of inheriting the mutation in question; and 4. The results of the genetic test would materially impact the medical management of the individual with resulting improvement in health outcomes; and 5. Testing is accompanied by genetic counseling. BRCA Mutation Testing may be considered medically necessary for individuals who meet criteria in any one of the following categories: A. Individuals with a personal history of cancer, genetic testing for a BRCA1 or BRCA2 mutation, associated with genetic counseling, when: 1. The individual has a history of breast cancer and at least 1 relative with breast cancer diagnosed prior to age 45; OR 2. The individual was diagnosed with breast cancer prior to age 50; OR 3. The individual has multiple primary breast cancers or bilateral breast cancer; OR 4. The individual is a male with breast cancer; OR 5. The individual has triple negative breast cancer diagnosed prior to age 60; OR 6. The individual has a history of breast cancer and 2 or more first-, second- or third-degree relatives with pancreatic cancer; OR 7. The individual has a history of ovarian, fallopian tube or primary peritoneal cancer; OR 8. The individual has a history of pancreatic cancer and 2 or more first-, second-, or third-degree relatives with breast and/or ovarian and/or pancreatic cancer; OR 9. The individual has a history of breast cancer and 2 or more first-, second- or third-degree relatives with breast or ovarian, fallopian tube, or primary peritoneal cancer; OR 10. The individual has a history of breast cancer and belongs to a population at risk for specific mutations due to ethnic background (for example, Ashkenazi Jewish, Icelandic, Swedish, Hungarian or Dutch descent). B. Individuals with a family history of cancer, genetic testing for a BRCA1 or BRCA2 mutation, associated with genetic counseling, who have a relative who would meet ANY of the following, but that relative is not available for testing: 1. The individual has a first- or second-degree relative with breast cancer who also had at least 1 relative with breast cancer diagnosed prior to age 45; OR 2. The individual has a first- or second-degree relative who had breast cancer diagnosed prior to age 50; OR 3. The individual has a first- or second-degree relative who had multiple primary breast cancers or bilateral breast cancer; OR 4. The individual has a first- or second-degree relative who has a history of ovarian, fallopian tube, or primary peritoneal cancer; OR 2

3 5. The individual has a first- or second-degree male relative who developed breast cancer; OR The individual has a first- or second-degree relative who had triple negative breast cancer diagnosed prior to age 60; OR 6. The individual has a first- or second-degree relative with a history of breast cancer and 2 or more first-, second-, or third-degree relatives with pancreatic cancer; OR 7. The individual has a first- or second-degree relative who has a history of ovarian cancer and 2 or more first- second- or third-degree relatives with pancreatic cancer; OR 8. The individual has a first- or second-degree relative with a history of pancreatic cancer and 2 or more first-, second-, or third-degree relatives with breast and/or ovarian and/or pancreatic cancer. C. Individuals with a family history of 3 or more first-, second- or third-degree relatives with ovarian, fallopian tube or primary peritoneal cancer or breast cancer, (at least one of which has breast cancer at or before age 50), genetic testing for a BRCA1 or BRCA2 mutation, associated with genetic counseling. Large genomic rearrangement testing (BART) to identify individuals at risk for BRCA1/2 related cancers is generally considered medically necessary for individuals who meet any of the criteria above for BRCA1/2 genetic sequence testing, but have negative results from that testing. Note: The U.S. Preventive Services Task Force recommends against routine referral for genetic counseling or routine breast cancer susceptibility (BRCA) testing for women whose family history is not associated with an increased risk for deleterious mutations in BRCA genes. NOTE: EPSDT Special Provision Early and Periodic Screening, Diagnosis, and Treatment (EPSDT) is a federal Medicaid requirement that requires the Connecticut Medical Assistance Program (CMAP) to cover services, products, or procedures for Medicaid enrollees under 21 years of age where the service or good is medically necessary health care to correct or ameliorate a defect, physical or mental illness, or a condition identified through a screening examination. The applicable definition of medical necessity is set forth in Conn. Gen. Stat. Section 17b-259b (2011) [ref. CMAP Provider Bulletin PB ]. PROCEDURE Prior authorization of BRCA Mutation Testing is required. Requests for coverage of BRCA Mutation Testing will be reviewed in accordance with procedures in place for reviewing requests for genetic testing. Coverage determinations will be based upon a review of requested and/or submitted casespecific information. The following information is needed to review requests for BRCA Mutation Testing: 1. Fully completed State of Connecticut, Department of Social Services Outpatient Prior Authorization Request form or fully completed prior authorization request via web portal; and 2. Clinical information supporting the need for requested services to include pertinent clinical and family history; and 3. Other information as requested by CHNCT. EFFECTIVE DATE This Policy is effective for prior authorization requests for BRCA Mutation Testing for individuals covered 3

4 under the HUSKY Health Program on or after January 1, LIMITATIONS Not Applicable CODES: Code Definition BRCA1, BRCA2 (breast cancer 1 and 2) (e.g., hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis BRCA 1, BRCA 2 (breast cancer 1 and 2) (e.g., hereditary breast and ovarian cancer) gene analysis; full sequence analysis and common duplication/deletion variants in BRCA1 (i.e., exon 13 del 3.835kb, exon 13 dup 6kb, exon del 26kb, exon 22 del 510bp, exon 8-9 del 7.1kb) BRCA 1, BRCA 2 (breast cancer 1 and 2) (e.g., hereditary breast and ovarian cancer) gene analysis; 185delAG, 5385insC, 6174delT variants BRCA 1, BRCA 2 (breast cancer 1 and 2) (e.g., hereditary breast and ovarian cancer) gene analysis; uncommon duplication/deletion variants BRCA1 (breast cancer 1) (e.g., hereditary breast and ovarian cancer) gene analysis; full sequence analysis and common duplication/deletion variants (i.e., exon 13del 3.835kb, exon 13 dup 6kb, exon del 26kb, exon 22 del 510bp, exon 8-9 del 7.1kb BRCA1 (breast cancer 1) (e.g., hereditary breast and ovarian cancer) gene analysis; known familial variant BRCA2 (breast cancer 2) (e.g., hereditary breast and ovarian cancer) gene analysis; full sequence analysis BRCA2 (breast cancer 2) (e.g., hereditary breast and ovarian cancer) gene analysis; known familial variant DEFINITIONS 1. BRCA Genes: BRCA genes include cancer susceptibility gene 1 (BRCA1) and/or breast cancer susceptibility gene 2 (BRCA2). 2. Breast Cancer: A cancer starting in the cells of breast tissue in females and males; for the purpose of BRCA mutation testing including invasive or ductal carcinoma in situ. 3. Close Blood Relative: A 1 st degree relative (i.e., mother, sister, daughter); or a 2 nd degree relative (i.e., aunt, grandmother, niece); or a 3 rd degree relative (i.e., first cousin, great parent). 4. Current Procedural Terminology (CPT): The most recent edition of a listing, published by the American Medical Association, of descriptive terms and identifying codes for reporting medical services performed by providers. 5. HUSKY A: Connecticut children and their parents or a relative caregiver; and pregnant women may qualify for HUSKY A (also known as Medicaid). Income limits apply. 6. HUSKY B: Uninsured children under the age of 19 in higher income households may be eligible for 4

5 HUSKY B (also known as the Children s Health Insurance Program) depending on their family income level. Family cost-sharing may apply. 7. HUSKY C: Connecticut residents who are age 65 or older or residents who are ages and who are blind, or have another disability, may qualify for Medicaid coverage under HUSKY C (this includes Medicaid for Employees with Disabilities (MED-Connect), if working). Income and asset limits apply. 8. HUSKY D: Connecticut residents who are ages without dependent children and who: (1) do not qualify for HUSKY A; (2) do not receive Medicare; and (3) are not pregnant, may qualify for HUSKY D (also known as Medicaid for the Lowest-Income populations). 9. HUSKY Health Program: The HUSKY A, HUSKY B, HUSKY C, HUSKY D and HUSKY Limited Benefit programs, collectively. 10. HUSKY Limited Benefit Program or HUSKY, LBP: Connecticut s implementation of limited health insurance coverage under Medicaid for individuals with tuberculosis or for family planning purposes and such coverage is substantially less than the full Medicaid coverage. 11. HUSKY Plus Physical Program (or HUSKY Plus Program): A supplemental physical health program pursuant to Conn. Gen. Stat. 17b-294, for medically eligible members of HUSKY B in Income Bands 1 and 2, whose intensive physical health needs cannot be accommodated within the HUSKY Plan, Part B. 12. Medically Necessary or Medical Necessity: (as defined in Connecticut General Statutes 17b- 259b) Those health services required to prevent, identify, diagnose, treat, rehabilitate or ameliorate an individual's medical condition, including mental illness, or its effects, in order to attain or maintain the individual's achievable health and independent functioning provided such services are: (1) Consistent with generally-accepted standards of medical practice that are defined as standards that are based on (A) credible scientific evidence published in peerreviewed medical literature that is generally recognized by the relevant medical community, (B) recommendations of a physician- specialty society, (C) the views of physicians practicing in relevant clinical areas, and (D) any other relevant factors; (2) clinically appropriate in terms of type, frequency, timing, site, extent and duration and considered effective for the individual's illness, injury or disease; (3) not primarily for the convenience of the individual, the individual's health care provider or other health care providers; (4) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the individual's illness, injury or disease; and (5) based on an assessment of the individual and his or her medical condition. 13. Ovarian Cancer: Ovarian cancer is a cancer of the ovary. For the purpose of BRCA mutation testing it includes both fallopian tube and primary peritoneal carcinoma. 14. Prior Authorization: A process for approving covered services prior to the delivery of the service or initiation of the plan of care based on a determination by CHNCT as to whether the requested service is medically necessary. ADDITIONAL RESOURCES AND REFERENCES: American Medical Association, Current Procedural Terminology Manual: 2016 DSS Provider Bulletin : Consolidated Laboratory Fee Schedule Update, dated June 2012 U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility. Agency for Healthcare Research and Quality: Rockville, MD; September American College of Medical Genetics (ACMG). Genetic susceptibility to breast and ovarian cancer: Assessment, counseling and testing guidelines. ACMG: Bethesda, MD; National Comprehensive Cancer Network (NCCN). Genetic/familial high-risk assessment: breast and ovarian. NCCN Clinical Practice Guidelines in Oncology. V

6 PUBLICATION HISTORY Status Date Action Taken Original publication October 2012 Reviewed December 2013 Clinical Quality Sub-Committee Review. Reference updated. These changes approved at the December 16, 2013 Clinical Quality Sub-Committee meeting. Reviewed December 2014 Clinical Quality Sub-Committee Review Reference updated. Change approved at the December 15, 2014 Clinical Quality Sub-Committee meeting. Updated August 2015 HUSKY Program definitions updated at request of DSS. Updated March 2016 Updates to language in introductory paragraph pertaining t purpose of policy. Updates to Clinical Guideline section pertaining to definition of Medical Necessity. Updates throughout policy to reflect importance of person-centeredness when reviewing requests for this service. Changes approved at the March 21, 2016 Clinical Quality Subcommittee meeting. Changes approved by DSS on April 11,

PROVIDER POLICIES & PROCEDURES

PROVIDER POLICIES & PROCEDURES PROVIDER POLICIES & PROCEDURES REHABILITATION SERVICES The primary purpose of this document is to assist providers enrolled in the Connecticut Medical Assistance Program (CMAP Providers) with the information

More information

PROVIDER POLICIES & PROCEDURES

PROVIDER POLICIES & PROCEDURES PROVIDER POLICIES & PROCEDURES COMPARATIVE GENOMIC HYBRIDIZATION (CGH) MICROARRAY TESTING FOR DEVELOPMENTAL DELAY, AUTISM SPECTRUM DISORDER AND INTELLECTUAL DISABILITY The purpose of this policy is to

More information

Policy Specific Section: Medical Necessity and Investigational / Experimental. October 15, 1997 October 9, 2013

Policy Specific Section: Medical Necessity and Investigational / Experimental. October 15, 1997 October 9, 2013 Medical Policy Genetic Testing for Hereditary Breast and/or Ovarian Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date:

More information

Genetic Testing for BRCA1 and BRCA2 Genes

Genetic Testing for BRCA1 and BRCA2 Genes Genetic Testing for BRCA1 and BRCA2 Genes MP9478 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below Pre and post-test genetic counseling

More information

BRCA Precertification Information Request Form

BRCA Precertification Information Request Form BRCA Precertification Information Request Form Failure to complete this form in its entirety may result in the delay of review. Fax to: BRCA Precertification Department Fax number: 1-860-975-9126 Section

More information

GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME BRCA1 BRCA2

GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME BRCA1 BRCA2 SYNDROME BRCA1 BRCA2 Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Genetic Testing for BRCA1 and BRCA2 Genes

Genetic Testing for BRCA1 and BRCA2 Genes Genetic Testing f BRCA1 and BRCA2 Genes MP9478 Covered Service: Pri Authization Required: Additional Infmation: Yes when meets criteria below Yes--as shown below Pre and post-test genetic counseling is

More information

PROVIDER POLICIES & PROCEDURES

PROVIDER POLICIES & PROCEDURES PROVIDER POLICIES & PROCEDURES TREATMENT OF VARICOSE VEINS OF THE LOWER EXTREMITIES STAB PHLEBECTOMY AND SCLEROTHERAPY TREATMENT The primary purpose of this document is to assist providers enrolled in

More information

PROVIDER POLICIES & PROCEDURES

PROVIDER POLICIES & PROCEDURES PROVIDER POLICIES & PROCEDURES GENETIC CANCER SUSCEPTIBILITY PANELS USING NEXT GENERATION SEQUENCING The purpose of this document is to assist providers enrolled in the Connecticut Medical Assistance Program

More information

Policy and Procedure. Department: Utilization Management. SNP, CHP, MetroPlus Gold, Goldcare I&II, Market Plus, Essential, HARP

Policy and Procedure. Department: Utilization Management. SNP, CHP, MetroPlus Gold, Goldcare I&II, Market Plus, Essential, HARP Retired Date: Page 1 of 9 1. POLICY DESCRIPTION: BRCA 1&2 Genetic Testing 2. RESPONSIBLE PARTIES: Medical Management Administration, Utilization Management, Integrated Care Management, Pharmacy, Claim

More information

GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER BRCA1 BRCA2

GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER BRCA1 BRCA2 GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER BRCA1 BRCA2 Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

Medical Policy Manual. Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer. Date of Origin: January 27, 2011

Medical Policy Manual. Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer. Date of Origin: January 27, 2011 Medical Policy Manual Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer Date of Origin: January 27, 2011 Section: Genetic Testing Last Reviewed Date: July 2014 Policy No: 02 Effective

More information

Applies to: All Aetna plans, except Traditional Choice plans. All Innovation Health plans, except indemnity plans

Applies to: All Aetna plans, except Traditional Choice plans. All Innovation Health plans, except indemnity plans BRCA Precertification Information Request Form Applies to: All Aetna plans, except Traditional Choice plans All Innovation Health plans, except indemnity plans All Health benefits and health insurance

More information

Corporate Medical Policy Genetic Testing for Breast and Ovarian Cancer

Corporate Medical Policy Genetic Testing for Breast and Ovarian Cancer Corporate Medical Policy Genetic Testing for Breast and Ovarian Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_breast_and_ovarian_cancer 8/1997 8/2017

More information

MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers

MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers POLICY: PG0067 ORIGINAL EFFECTIVE: 07/30/02 LAST REVIEW: 01/25/18 MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers GUIDELINES This policy does not certify benefits or authorization of benefits,

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association BRCA1 and BRCA2 Testing Page 1 of 26 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: BRCA1 and BRCA2 Testing Pre-Determination of Services IS REQUIRED by the Member

More information

Sporadic Cancer - Cancer which occurs by chance. People with sporadic cancer typically do not have relatives with the same type of cancer.

Sporadic Cancer - Cancer which occurs by chance. People with sporadic cancer typically do not have relatives with the same type of cancer. to risk assessment Hereditary Cancer Testing: Is it Right for You? This workbook is designed to help you decide if hereditary cancer testing is right for you and should be reviewed with a trained healthcare

More information

GENETIC TESTING FOR HEREDITARY CANCER

GENETIC TESTING FOR HEREDITARY CANCER UnitedHealthcare Oxford Clinical Policy GENETIC TESTING FOR HEREDITARY CANCER Policy Number: DIAGNOSTIC 004.27 T2 Effective Date: November 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS

More information

Utilization of BRCA Testing. Breast and Ovarian Cancer in Texas

Utilization of BRCA Testing. Breast and Ovarian Cancer in Texas Utilization of BRCA Testing in Older Ode Women with Breast and Ovarian Cancer in Texas Ana M. Rodriguez, MD Assistant Professor Department of Obstetrics and Gynecology University of Texas Medical Branch

More information

HBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond.

HBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond. HBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond. Conni Murphy, ARNP Cancer Risk Assessment and Genetics Program Jupiter Medical Center Learning Objectives Identify

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY BRCA1 and BRCA2 Genetic Mutation Testing and Related Genetic Counseling MP-011-MD-DE Medical Management Provider Notice Date:

More information

MP Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers

MP Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers Medical Policy MP 2.04.02 Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk BCBSA Ref. Policy: 2.04.02 Last Review: 11/15/2018 Effective Date: 02/15/2019

More information

PROVIDER POLICIES & PROCEDURES

PROVIDER POLICIES & PROCEDURES PROVIDER POLICIES & PROCEDURES GENDER REASSIGNMENT SURGERY The primary purpose of this policy is to assist providers enrolled in the Connecticut Medical Assistance Program (CMAP) with the information needed

More information

POSITIVE DELETERIOUS MUTATION

POSITIVE DELETERIOUS MUTATION Understanding Your Genetic Test Result Positive for a Deleterious or Suspected Deleterious POSITIVE DELETERIOUS MUTATION This workbook is designed to help you understand the results of your genetic test

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association BRCA1 and BRCA2 Testing Page 1 of 33 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: BRCA1 and BRCA2 Testing Pre-Determination of Services IS REQUIRED by the Member

More information

Does Cancer Run in Your Family?

Does Cancer Run in Your Family? Does Cancer Run in Your Family? A Patient s Guide to Hereditary Breast and Ovarian Cancer Syndrome What is Hereditary Cancer? Most cancers occur in people who do not have a strong family history of that

More information

The impact of hereditary breast and ovarian cancer (HBOC) syndrome testing on patient management and your practice

The impact of hereditary breast and ovarian cancer (HBOC) syndrome testing on patient management and your practice The impact of hereditary breast and ovarian cancer (HBOC) syndrome testing on patient management and your practice Use BRACAnalysis as a guide in your medical and surgical management BRACAnalysis testing

More information

BRCAnowTM It s Your Decision

BRCAnowTM It s Your Decision Hereditary Breast and Ovarian Cancer BRCAnowTM It s Your Decision Patient & Physician Information What is BRCA? The breast cancer genes BRCA1 and BRCA2 are found within an individual s normal genetic makeup;

More information

Understanding Your Genetic Test Result. Positive for a Deleterious Mutation or Suspected Deleterious

Understanding Your Genetic Test Result. Positive for a Deleterious Mutation or Suspected Deleterious Understanding Your Genetic Test Result Positive for a Deleterious Mutation or Suspected Deleterious This workbook is designed to help you understand the results of your genetic test and is best reviewed

More information

Understanding Your Genetic Test Result. Positive for a Deleterious Mutation or Suspected Deleterious

Understanding Your Genetic Test Result. Positive for a Deleterious Mutation or Suspected Deleterious Understanding Your Genetic Test Result Positive for a Deleterious Mutation or Suspected Deleterious This workbook is designed to help you understand the results of your genetic test and is best reviewed

More information

MEDICAL POLICY SUBJECT: GENETIC TESTING FOR HEREDITARY BRCA MUTATIONS. POLICY NUMBER: CATEGORY: Laboratory Test

MEDICAL POLICY SUBJECT: GENETIC TESTING FOR HEREDITARY BRCA MUTATIONS. POLICY NUMBER: CATEGORY: Laboratory Test MEDICAL POLICY SUBJECT: GENETIC TESTING FOR HEREDITARY BRCA MUTATIONS POLICY NUMBER: 2.02.06 CATEGORY: Laboratory Test EFFECTIVE DATE: 01/17/02 REVISED DATE: 08/21/03, 09/16/04, 08/18/05, 06/15/06, 04/17/14,

More information

Hereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG

Hereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG Hereditary Breast and Ovarian Cancer 2015 Rebecca Sutphen, MD, FACMG Among a consecutive series of 11,159 women requesting BRCA testing over one year, 3874 responded to a mailed survey. Most respondents

More information

Policy #: 259 Latest Review Date: November 2009

Policy #: 259 Latest Review Date: November 2009 Name of Policy: Prophylactic Oophorectomy Policy #: 259 Latest Review Date: November 2009 Category: Surgery Policy Grade: Active Policy but no longer scheduled for regular literature reviews and updates.

More information

Genetic Screening Visit

Genetic Screening Visit Before your visit In a typical hereditary breast ovarian cancer genetic counsling visit be prepared to answer the following set of questions, please check were applicable. About your self (same questions

More information

A Patient s Guide to. Hereditary Ovarian Cancer: Is Hereditary Cancer Testing Right for You?

A Patient s Guide to. Hereditary Ovarian Cancer: Is Hereditary Cancer Testing Right for You? A Patient s Guide to Hereditary Ovarian Cancer: Is Hereditary Cancer Testing Right for You? What is Hereditary Cancer? Most cancers occur in people who do not have a strong family history of that cancer.

More information

Clinical Policy Title: Genetic testing for breast and ovarian cancer

Clinical Policy Title: Genetic testing for breast and ovarian cancer Clinical Policy Title: Genetic testing for breast and ovarian cancer Clinical Policy Number: 02.01.02 Effective Date: September 1, 2013 Initial Review Date: March 21, 2013 Most Recent Review Date: May

More information

Outline. Identifying your risk for hereditary breast or ovarian cancer. Genetics 101. What causes cancer? Genetics

Outline. Identifying your risk for hereditary breast or ovarian cancer. Genetics 101. What causes cancer? Genetics Identifying your risk for hereditary breast or ovarian cancer David Andorsky, MD Breanna Roscow, MS, CGC 303-993-0161 Outline Genetics and biology of hereditary cancer syndromes BRCA1 and BRCA2 Genetic

More information

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. MRI OF THE BREAST Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

GeneticsNow TM. A Guide to Testing Hereditary Conditions in Women & Men. Patient & Physician Information

GeneticsNow TM. A Guide to Testing Hereditary Conditions in Women & Men. Patient & Physician Information GeneticsNow TM A Guide to Testing Hereditary Conditions in Women & Men Patient & Physician Information How can BRCA status affect your health? Everyone has BRCA1 and BRCA2 genes. However, sometimes the

More information

patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015

patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015 patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015 BRCA1 and BRCA2 Mutations Cancer is a complex disease thought to be caused by several different factors. A few types of cancer

More information

The Genetics of Breast and Ovarian Cancer Prof. Piri L. Welcsh

The Genetics of Breast and Ovarian Cancer Prof. Piri L. Welcsh The Genetics of Breast Piri L. Welcsh, PhD Research Assistant Professor University of Washington School of Medicine Division of Medical Genetics 1 Genetics of cancer All cancers arise from genetic and

More information

6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017

6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017 Genetics 101 Hereditary Breast and Ovarian Cancer 2017 Rebecca Sutphen, MD, FACMG Professor, College of Medicine President & Chief Medical Officer INVASIVE CANCER GENETICALLY ALTERED CELL HYPERPLASIA DYSPLASIA

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Moderate Penetrance Variants Associated with Breast Cancer in File Name: Origination: Last CAP Review: Next CAP Review: Last Review: moderate_penetrance_variants_associated_with_breast_cancer_

More information

So how much of breast and ovarian cancer is hereditary? A). 5 to 10 percent. B). 20 to 30 percent. C). 50 percent. Or D). 65 to 70 percent.

So how much of breast and ovarian cancer is hereditary? A). 5 to 10 percent. B). 20 to 30 percent. C). 50 percent. Or D). 65 to 70 percent. Welcome. My name is Amanda Brandt. I am one of the Cancer Genetic Counselors at the University of Texas MD Anderson Cancer Center. Today, we are going to be discussing how to identify patients at high

More information

So, now, that we have reviewed some basics of cancer genetics I will provide an overview of some common syndromes.

So, now, that we have reviewed some basics of cancer genetics I will provide an overview of some common syndromes. Hello. My name is Maureen Mork and I m a Certified Genetic Counselor in the Clinical Cancer Genetics Program at The University of Texas MD Anderson Cancer Center. I ll be lecturing today on the Cancer

More information

HBOC. Jessica M. Salamone, ScM, CGC

HBOC. Jessica M. Salamone, ScM, CGC HBOC Jessica M. Salamone, ScM, CGC Certified Genetic Counselor Director of the Cancer Risk Assessment & Genetic Counseling Program Elizabeth Wende Breast Care, LLC Elizabeth Wende Breast Care Internationally

More information

Eligibility criteria for prophylactic treatment allowance

Eligibility criteria for prophylactic treatment allowance Eligibility criteria for prophylactic treatment allowance Southern Cross will only pay the prophylactic treatment allowance for the following healthcare services when the applicable eligibility criteria

More information

Precision Medicine and Genetic Counseling : Is Yes always the correct answer?

Precision Medicine and Genetic Counseling : Is Yes always the correct answer? Precision Medicine and Genetic Counseling : Is Yes always the correct answer? Beverly M. Yashar, MS, PhD, CGC Director, Graduate Program in Genetic Counseling Professor, Department of Human Genetics. (yashar@umich.edu)

More information

Breast Cancer Risk Assessment: Genetics, Risk Models, and Screening. Amie Hass, MSN, ARNP, FNP-BC Hall-Perrine Cancer Center

Breast Cancer Risk Assessment: Genetics, Risk Models, and Screening. Amie Hass, MSN, ARNP, FNP-BC Hall-Perrine Cancer Center Breast Cancer Risk Assessment: Genetics, Risk Models, and Screening Amie Hass, MSN, ARNP, FNP-BC Hall-Perrine Cancer Center Disclosure- I DO NOT HAVE any relevant financial interest with any entity producing,

More information

BRCA1 & BRCA2: CANCER RISK & GENETIC TESTING IAP ID 2013 NAIR HOSPITAL, MUMBAI

BRCA1 & BRCA2: CANCER RISK & GENETIC TESTING IAP ID 2013 NAIR HOSPITAL, MUMBAI BRCA1 & BRCA2: CANCER RISK & GENETIC TESTING IAP ID 2013 NAIR HOSPITAL, MUMBAI DR KIRTI CHADHA MD (Path), PDCC (Oncopath & Oncohemat) CONSULTANT SURGICAL PATHOLOGIST NATIONAL COORDINATOR,SURGICAL PATHOLOGY

More information

GENETIC TESTING AND COUNSELING FOR HERITABLE DISORDERS

GENETIC TESTING AND COUNSELING FOR HERITABLE DISORDERS Status Active Medical and Behavioral Health Policy Section: Laboratory Policy Number: VI-09 Effective Date: 03/17/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members

More information

Primary Care Approach to Genetic Cancer Syndromes

Primary Care Approach to Genetic Cancer Syndromes Primary Care Approach to Genetic Cancer Syndromes Jason M. Goldman, MD, FACP FAU School of Medicine Syndromes Hereditary Breast and Ovarian Cancer (HBOC) Hereditary Nonpolyposis Colorectal Cancer (HNPCC)

More information

I have ovarian cancer

I have ovarian cancer I have ovarian cancer Everything you need to know about BRCA1/2 gene mutations (Scotland only) 1 An introduction to BRCA1/2 gene mutations BRCA1 and BRCA2 are genes that repair damage in cells and prevent

More information

HEREDITY & CANCER: Breast cancer as a model

HEREDITY & CANCER: Breast cancer as a model HEREDITY & CANCER: Breast cancer as a model Pierre O. Chappuis, MD Divisions of Oncology and Medical Genetics University Hospitals of Geneva, Switzerland Genetics, Cancer and Heredity Cancers are genetic

More information

Does Cancer Run in Your Family?

Does Cancer Run in Your Family? Does Cancer Run in Your Family? Nancie Petrucelli, MS, CGC Clinical Assistant Professor Certified Genetic Counselor/Coordinator Cancer Genetic Counseling Service Karmanos Cancer Institute Wayne State University

More information

patient education Fact Sheet

patient education Fact Sheet patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations OCTOBER 2017 BRCA1 and BRCA2 Mutations Cancer is caused by several different factors. A few types of cancer run in families. These types are

More information

Genetic Testing of Inherited Cancer Predisposition Genetic Testing - Oncology

Genetic Testing of Inherited Cancer Predisposition Genetic Testing - Oncology Genetic Testing of Inherited Cancer Predisposition Genetic Testing - Oncology Policy Number: Original Effective Date: MM.02.010 05/01/2010 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration

More information

Re: NC Medicaid and NC Health Choice Program coverage of genetic testing for susceptibility to breast and ovarian cancer

Re: NC Medicaid and NC Health Choice Program coverage of genetic testing for susceptibility to breast and ovarian cancer March 23, 2018 North Carolina (NC) Division of Medical Assistance (DMA), Clinical Policy Section C/O Pam Greeson, BSN, RN-C, pam.greeson@dhhs.nc.gov Nurse Consultant, Division of Medical Assistance Practitioners,

More information

Importance of Family History in Gynecologic Cancer Prevention. Objectives. Genetic Counselors. Angela Thompson, MS, CGC

Importance of Family History in Gynecologic Cancer Prevention. Objectives. Genetic Counselors. Angela Thompson, MS, CGC Importance of Family History in Gynecologic Cancer Prevention Angela Thompson, MS, CGC Genetic Counselor Froedtert & The Medical College of Wisconsin Objectives Introduce role of genetic counselor Discuss

More information

Cancer Survivorship Symposium Cancer and Heredity January 16, Jeanne P. Homer, MS Licensed Certified Genetic Counselor

Cancer Survivorship Symposium Cancer and Heredity January 16, Jeanne P. Homer, MS Licensed Certified Genetic Counselor Cancer Survivorship Symposium Cancer and Heredity January 16, 2017 Jeanne P. Homer, MS Licensed Certified Genetic Counselor Outline Cancer and Heredity Hereditary Cancer Risk Assessment & Genetic testing

More information

Jill Stopfer, MS, CGC Abramson Cancer Center University of Pennsylvania

Jill Stopfer, MS, CGC Abramson Cancer Center University of Pennsylvania Jill Stopfer, MS, CGC Abramson Cancer Center University of Pennsylvania Aging Family history Early menarche Late menopause Nulliparity Estrogen / Progesterone use after menopause More than two alcoholic

More information

I have ovarian cancer

I have ovarian cancer I have ovarian cancer Everything you need to know about BRCA1/2 gene mutations (NHS England only) 1 An introduction to BRCA1/2 gene mutations BRCA1 and BRCA2 are genes that repair damage in cells and prevent

More information

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Local Coverage Determination (LCD): Pathology and Laboratory: BRCA1 and BRCA2 Genetic Testing (L36741) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

More information

30 TPHA Journal Volume 65, Issue 2

30 TPHA Journal Volume 65, Issue 2 Utilization of BRCA testing in older women with breast and/or ovarian cancer in the state of Texas Ana M. Rodriguez,¹ Sharon H. Giordano,² and Catherine D. Cooksley³ ¹Department of Obstetrics & Gynecology,

More information

GENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER. Dr Abhijit Dixit. Family Health Clinical Genetics

GENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER. Dr Abhijit Dixit. Family Health Clinical Genetics GENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review

More information

Genetic Determinants, Risk Assessment and Management

Genetic Determinants, Risk Assessment and Management Genetic Determinants, Risk Assessment and Management Rachel Rando, MS, CGC Genetic Counselor Hunterdon Regional Cancer Center Flemington, NJ I have no disclosures. Acknowledgements: Staff of Hunterdon

More information

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Local Coverage Determination (LCD): MolDX: BRCA1 and BRCA2 Genetic Testing (L36161) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information

More information

BRCA1 and BRCA2. patient guide. genetic testing for hereditary breast and ovarian cancer (hboc)

BRCA1 and BRCA2. patient guide. genetic testing for hereditary breast and ovarian cancer (hboc) patient guide BRCA1 and BRCA2 genetic testing for hereditary breast and ovarian cancer (hboc) Because knowing your risk can mean early detection and prevention Know the Basics People with HBOC may have

More information

Chapter 18 Section 13

Chapter 18 Section 13 Demonstrations Chapter 18 Section 13 TRICARE Evaluation Of Centers For Medicare And Medicaid Services (CMS) Approved Laboratory Developed Tests (LDTs) Demonstration Project 1.0 PURPOSE The purpose of the

More information

A Patient s Guide to Hereditary Cancer. Is Hereditary Cancer Testing Right for You?

A Patient s Guide to Hereditary Cancer. Is Hereditary Cancer Testing Right for You? A Patient s Guide to Hereditary Cancer Is Hereditary Cancer Testing Right for You? What is Hereditary Cancer? Most cancers occur in people who do not have a strong family history of that cancer. This is

More information

Cancer Genetics Baylor All Saints Medical Center at Fort Worth

Cancer Genetics Baylor All Saints Medical Center at Fort Worth Cancer Genetics Baylor All Saints Medical Center at Fort Worth Thank you for your interest in the Hereditary Cancer Risk Program (HCRP). Please complete the family history and risk factor questionnaire

More information

Prophylactic Mastectomy

Prophylactic Mastectomy Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO 07/22/2011 Section: Surgery Place(s) of Service: Inpatient I.

More information

Genetic Testing for Hereditary Breast and/or Ovarian Cancer

Genetic Testing for Hereditary Breast and/or Ovarian Cancer Genetic Testing for Hereditary Breast and/or Ovarian Cancer Policy Number: Original Effective Date: MM.02.008 07/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/15/2017

More information

Notes for slide 2 Welcome to today s training webinar. We appreciate everyone taking time today to hear our presentations. We are very excited to fina

Notes for slide 2 Welcome to today s training webinar. We appreciate everyone taking time today to hear our presentations. We are very excited to fina Notes for slide 2 Welcome to today s training webinar. We appreciate everyone taking time today to hear our presentations. We are very excited to finally be able to put these genomics related data items

More information

BRCA2 gene. Associated Syndrome Name: Hereditary Breast and Ovarian Cancer syndrome (HBOC) BRCA2 Summary Cancer Risk Table. BRCA2 gene Overview

BRCA2 gene. Associated Syndrome Name: Hereditary Breast and Ovarian Cancer syndrome (HBOC) BRCA2 Summary Cancer Risk Table. BRCA2 gene Overview BRCA gene Associated Syndrome Name: Hereditary Breast and Cancer syndrome (HBOC) BRCA Summary Cancer Risk Table Male Breast GENETIC RISK Female Breast Elevated Risk Elevated Risk BRCA gene Overview Hereditary

More information

The Importance of Iden0fying Women at Risk for BRCA1/2 Muta0ons for Referral to Cancer Gene0cs Services

The Importance of Iden0fying Women at Risk for BRCA1/2 Muta0ons for Referral to Cancer Gene0cs Services The Importance of Iden0fying Women at Risk for BRCA1/2 Muta0ons for Referral to Cancer Gene0cs Services Cecelia Bellcross, PhD, MS, CGC Emory University School of Medicine Department of Human Gene0cs Alliance

More information

Page 1 of 5 Home > Research & Grants > Research and Scientific Programs > What is genetic testing for breast cancer and who should get it? What is genetic testing for breast cancer and who should get it?

More information

Family Planning Eligibility Program

Family Planning Eligibility Program INDIANA HEALTH COVERAGE PROGRAMS PROVIDER REFERENCE M ODULE Family Planning Eligibility Program L I B R A R Y R E F E R E N C E N U M B E R : P R O M O D 0 0 0 5 3 P U B L I S H E D : N O V E M B E R 2

More information

Contractor Information

Contractor Information Local Coverage Determination (LCD): MolDX: BRCA1 and BRCA2 Genetic Testing (L36163) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information

More information

Genetic Testing: who, what, why?

Genetic Testing: who, what, why? Genetic Testing: who, what, why? Gina Westhoff MD LMG Gynecologic Oncology March 16, 2019 Disclosures Speaker for Merck (unrelated to today s topic) Objectives Determine who should undergo genetic risk

More information

GENETIC TESTING FOR PREDICTING RISK OF NONFAMILIAL BREAST CANCER

GENETIC TESTING FOR PREDICTING RISK OF NONFAMILIAL BREAST CANCER Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent upon

More information

Contractor Information. LCD Information. Local Coverage Determination (LCD): MolDX: BRCA1 and BRCA2 Genetic Testing (L36082) Document Information

Contractor Information. LCD Information. Local Coverage Determination (LCD): MolDX: BRCA1 and BRCA2 Genetic Testing (L36082) Document Information Local Coverage Determination (LCD): MolDX: BRCA1 and BRCA2 Genetic Testing (L36082) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information

More information

CANCER GENETICS PROVIDER SURVEY

CANCER GENETICS PROVIDER SURVEY Dear Participant, Previously you agreed to participate in an evaluation of an education program we developed for primary care providers on the topic of cancer genetics. This is an IRB-approved, CDCfunded

More information

Report to the Social Services Appropriations Subcommittee

Report to the Social Services Appropriations Subcommittee Report to the Social Services Appropriations Subcommittee Medicaid Coverage and Reimbursement for Outpatient Physical Therapy and Outpatient Occupational Therapy Prepared by the Division of Medicaid and

More information

Result Navigator. Positive Test Result: RAD51C. After a positive test result, there can be many questions about what to do next. Navigate Your Results

Result Navigator. Positive Test Result: RAD51C. After a positive test result, there can be many questions about what to do next. Navigate Your Results Result Navigator Positive Test Result: RAD51C Positive test results identify a change, or misspelling, of DNA that is known or predicted to cause an increased risk for cancer. DNA is the blueprint of life

More information

Updates in Cancer Genetics & Genomics

Updates in Cancer Genetics & Genomics Updates in Cancer Genetics & Genomics Jennifer R. Klemp, PhD, MPH, MA Associate Professor of Medicine, Division of Clinical Oncology Director, Cancer Survivorship Co-Program Leader, Cancer Prevention and

More information

Please read the following instructions carefully

Please read the following instructions carefully Grand River Regional Cancer Centre 835 King Street West, PO Box 9056 Kitchener, ON N2G 1G3 Tel: (519) 749-4370 x2832 Fax: (519) 749-4394 Dear: You have been referred to the High Risk Ontario Breast Screening

More information

What You Need to Know About Ovarian Cancer

What You Need to Know About Ovarian Cancer What You Need to Know About Ovarian Cancer About Us The Rhode Island Ovarian Cancer Alliance (RIOCA) was formed in honor and memory of Jessica Morris. Jessica was diagnosed with Stage IIIC Ovarian Cancer

More information

Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families

Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families What is Hereditary Breast and Ovarian Cancer (HBOC)? Hereditary Breast and Ovarian Cancer is a genetic condition which

More information

Lori Carpenter, MS, LCGC Saint Francis Hospital

Lori Carpenter, MS, LCGC Saint Francis Hospital Lori Carpenter, MS, LCGC Saint Francis Hospital What is cancer genetic counseling Myth 1: Breast cancer is inevitable in my family Myth 2: My family history is on my dad s side, so it doesn t count Myth

More information

Screening for Genes for Hereditary Breast and Ovarian Cancer in Jewish Women

Screening for Genes for Hereditary Breast and Ovarian Cancer in Jewish Women Screening for Genes for Hereditary Breast and Ovarian Cancer in Jewish Women Background About 5% of women in Canada with breast cancer and about 12% of women with ovarian cancer, are born with an inherited

More information

Inherited Ovarian Cancer Diagnosis and Prevention

Inherited Ovarian Cancer Diagnosis and Prevention Inherited Ovarian Cancer Diagnosis and Prevention Dr. Jacob Korach - Deputy director Gynecologic Oncology (past chair - Israeli Society of Gynecologic Oncology) Prof. Eitan Friedman - Head, Oncogenetics

More information

MP Genetic Testing for Hereditary Breast/Ovarian Cancer Syndrome (BRCA1 or BRCA2)

MP Genetic Testing for Hereditary Breast/Ovarian Cancer Syndrome (BRCA1 or BRCA2) Medical Policy MP 2.04.02 BCBSA Ref. Policy: 2.04.02 Last Review: 11/30/2017 Effective Date: 11/30/2017 Section: Medicine End Date: 02/14/2019 Related Policies 2.04.93 Genetic Cancer Susceptibility Panels

More information

Clinical Quality Assurance Measures at Myriad Genetic Laboratories:

Clinical Quality Assurance Measures at Myriad Genetic Laboratories: Clinical Quality Assurance Measures at Myriad Genetic Laboratories: Increasing the Clinical Utility and Cost-Effectiveness of Genetic Testing for Hereditary Cancer Syndromes for Patients, Healthcare Providers

More information

Genetics and Cancer Care. Cynthia Forster-Gibson, MD, PhD and Loren Mackay- Loder, MSc Genetics Program, THP

Genetics and Cancer Care. Cynthia Forster-Gibson, MD, PhD and Loren Mackay- Loder, MSc Genetics Program, THP Genetics and Cancer Care Cynthia Forster-Gibson, MD, PhD and Loren Mackay- Loder, MSc Genetics Program, THP Faculty/Presenter Disclosure Faculty: Cynthia Forster-Gibson Relationships with commercial interests:

More information

Welcome! Here s our agenda for today:

Welcome! Here s our agenda for today: Welcome! Here s our agenda for today: What is ovarian cancer? What causes it? When does genetic testing come in? When are families at risk for ovarian cancer? What are the treatments? 3 things to remember

More information

Genetic Testing for Hereditary Breast and/or Ovarian Cancer Syndrome (BRCA1 or BRCA2)

Genetic Testing for Hereditary Breast and/or Ovarian Cancer Syndrome (BRCA1 or BRCA2) Genetic Testing for Hereditary Breast and/or Ovarian Cancer Syndrome (BRCA1 or BRCA2) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary,

More information

Knowledge, Attitudes, and Utilization of BRCA Testing Among Obstetricians and Gynecologists

Knowledge, Attitudes, and Utilization of BRCA Testing Among Obstetricians and Gynecologists Texas Medical Center Library DigitalCommons@TMC UT GSBS Dissertations and Theses (Open Access) Graduate School of Biomedical Sciences 5-2012 Knowledge, Attitudes, and Utilization of BRCA Testing Among

More information